Search research articles
Contact Us
Filters
Showing results (11-20 of 337) with videos related to
Page
of 34
Sort By:
Annals of the Rheumatic Diseases
|
October 22, 2005
The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
R N Maini
Rheumatology (Oxford, England)
|
January 26, 2000
Workshop summary: health outcomes and health economic issues surrounding the use of biological therapies in patients with rheumatoid arthritis
R N Maini, F Wolfe
Springer Seminars in Immunopathology
|
December 4, 1998
Rheumatoid arthritis: introduction
M Feldmann, R N Maini
Lancet (London, England)
|
September 21, 1996
Cytokine therapy in rheumatoid arthritis
R N Maini, M Feldmann
Annual Review of Immunology
|
March 13, 2001
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
M Feldmann, R N Maini
International Journal of Clinical Practice
|
May 16, 2001
Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)
J Bondeson, R N Maini
Rheumatology (Oxford, England)
|
January 26, 2000
The role of cytokines in the pathogenesis of rheumatoid arthritis
M Feldmann, R N Maini
The Netherlands Journal of Medicine
|
January 1, 1984
Circulating immune complexes (CIC) in connective tissue diseases (CTD)
L Schrieber, R N Maini
Bailliere'S Clinical Rheumatology
|
November 1, 1995
Anti-cytokine therapy in rheumatoid arthritis
M J Elliott, R N Maini
Advances in Experimental Medicine and Biology
|
January 1, 1993
Antibodies to neutrophil cytoplasmic antigens in rheumatoid arthritis
P J Charles, R N Maini
Page
of 34
Search research articles
Search
Showing results (11-20 of 337) with videos related to
Sort By:
Page
of 34
Annals of the Rheumatic Diseases
|
October 22, 2005
The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
R N Maini
Rheumatology (Oxford, England)
|
January 26, 2000
Workshop summary: health outcomes and health economic issues surrounding the use of biological therapies in patients with rheumatoid arthritis
R N Maini, F Wolfe
Springer Seminars in Immunopathology
|
December 4, 1998
Rheumatoid arthritis: introduction
M Feldmann, R N Maini
Lancet (London, England)
|
September 21, 1996
Cytokine therapy in rheumatoid arthritis
R N Maini, M Feldmann
Annual Review of Immunology
|
March 13, 2001
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
M Feldmann, R N Maini
International Journal of Clinical Practice
|
May 16, 2001
Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)
J Bondeson, R N Maini
Rheumatology (Oxford, England)
|
January 26, 2000
The role of cytokines in the pathogenesis of rheumatoid arthritis
M Feldmann, R N Maini
The Netherlands Journal of Medicine
|
January 1, 1984
Circulating immune complexes (CIC) in connective tissue diseases (CTD)
L Schrieber, R N Maini
Bailliere'S Clinical Rheumatology
|
November 1, 1995
Anti-cytokine therapy in rheumatoid arthritis
M J Elliott, R N Maini
Advances in Experimental Medicine and Biology
|
January 1, 1993
Antibodies to neutrophil cytoplasmic antigens in rheumatoid arthritis
P J Charles, R N Maini
Page
of 34